-in the complex therapy of acute respiratory viral infections (ARVIs)
-seasonal epidemics
Pharmacological properties
Recombinant interferon alpha-2b is a highly purified water-soluble protein with a molecular weight of 19,300 da.
It has antiproliferative effect on tumor cells, and also has antiviral and immunomodulating effects. The action of interferon alpha-2b is manifested by binding to specific receptors on the cell surface membrane and initiating a complex of sequential intracellular reactions associated with the induction of a number of enzymes and the implementation of cellular functions, namely: suppressing virus replication in an infected cell and reducing tumor cell proliferation; with the implementation of immunomodulatory processes (increased phagocytic activity of macrophages, increased specific cytotoxicity of lymphocytes to target cells).
Indications
The drug is used in complex therapy in adults and children with:
acute and chronic viral hepatitis B (moderate and severe forms);
chronic hepatitis C;
acute and chronic septic diseases of a viral nature;
acute viral, bacterial and mixed infections, including in newborns;
acute and chronic septic diseases of viral and bacterial etiology, including the diminished forms of acute and chronic sepsis;
herpes infections of various localization (herpes zoster, multiple skin herpetic eruptions, genital herpes, herpetic keratoconjunctivitis and keratouveitis);
laryngeal papillomatosis;
multiple sclerosis;
malignant melanoma, uveal melanoma, renal cell carcinoma, superficially localized bladder cancer, ovarian and breast cancer, Kaposi’s sarcoma due to HIV infection, chronic myelogenous leukemia, hairy cell leukemia, non-Hodgkin’s lymphoma, basal cell carcinoma, lymphoma cell carcinoma, mycosis).
Application
The drug is used in the form of a solution. Laferobion solution is administered intravenously (drip), intramuscularly, subcutaneous, intradermally, intraperitoneally, intravesical, rectal, intranasal, subconjunctival.
Laferobion 100,000 IU for Intranasal Use
SARS in children, including newborns
Intranasally, 4–6 drops in each nasal passage 3–6 times a day for 3–5 days; the dosage of the drug for newborns is 20,000-50,000 IU / ml, for other children - 100,000 IU / ml. It is permissible to introduce into the nasal passages (alternately) cotton turundas moistened with Laferobion solution for 10-15 minutes.
SARS in adults
Intranasally 0.25 ml of Laferobion solution (100,000 ME / ml) in each nasal passage 6-8 times a day. Before use, the administered Laferobion solution should be heated in a syringe (use a syringe without a needle) to body temperature, the remainder of the solution should be stored in the refrigerator, protecting from bacterial contamination.